Abstract

EDGE MEDICAL-B will release its second-quarter 2026 results post-Market on August 28, 2026; this preview highlights expected revenue growth, margin dynamics, and the balance of institutional opinions.

Market Forecast

Based on recent disclosures and the company’s last reported figures, the market anticipates sequential revenue growth for the quarter ending June 2026 with a gross profit margin broadly in the mid-to-high 60% range, a net loss close to breakeven levels, and a modest improvement in adjusted EPS year over year. Revenue for the quarter is likely anchored by surgical and medical equipment sales, with improving operating leverage from scale and cost optimization initiatives. The most promising segment remains the multi-port endoscopic surgical robot, which led revenue expansion and is expected to grow at a high double-digit to triple-digit rate year over year, supported by domestic installations and early overseas traction.

Last Quarter Review

In the prior quarter, EDGE MEDICAL-B reported revenue of 0.46 billion RMB, a gross profit margin of 67.51%, a GAAP net profit attributable to the parent company of 0.00 million RMB, a net profit margin of 0.16%, and adjusted EPS that improved year over year from a deeper loss base. A key highlight was continued expansion in unit placements and utilization of surgical robotic systems, which narrowed operating losses materially on a comparable basis. Main business performance was driven by Surgical & Medical Equipment revenue of 0.46 billion RMB, reflecting strong adoption momentum in core product lines compared with the prior year.

Current Quarter Outlook

Main business: Surgical and medical equipment revenue expansion

EDGE MEDICAL-B’s core business centers on surgical and medical equipment, where the company’s scaling production and broader hospital adoption are pivotal for near-term growth. The company’s pricing strategy and cost controls are helping preserve a gross margin profile in the mid-to-high 60% range, which provides cushion for reinvestment while narrowing losses. As installation bases expand, recurring revenue from instruments and consumables has the potential to lift revenue stability and improve blended margins, supporting a gradual path toward profitability.

Most promising segment: Multi-port endoscopic surgical robot

The multi-port endoscopic surgical robot remains the primary engine for growth, as indicated by the outsized contribution to revenue and rapid year-over-year increases reported in the past year. Domestic tenders and clinical expansions, paired with early overseas orders, underpin a pipeline that could sustain high growth as production throughput ramps and delivery timelines shorten. Software upgrades, surgeon training, and service contracts can further enhance revenue per installed system and drive higher utilization, improving the mix toward higher-margin recurring revenue.

Stock-price drivers this quarter: Shipments, margins, and cash discipline

Investors are likely to focus on the pace of system shipments and signed purchase agreements, which will signal demand durability and conversion from pipeline to revenue. Margin trajectory will be closely watched, particularly whether gross margin can sustain near the prior quarter’s level while operating expenses grow more slowly than revenue. Liquidity and cash burn trends remain important; reduced operating losses alongside improving working capital efficiency would bolster confidence in execution and runway into the second half of 2026.

Analyst Opinions

The balance of institutional commentary in recent months has been cautiously positive, emphasizing narrowing losses and robust revenue growth from surgical robotics. Commentary has noted that revenue more than doubled year over year with improved gross margin and a significantly narrowed operating loss, aligning with expectations of continued momentum into mid-2026. The constructive view centers on shipment acceleration, improving cost discipline, and the expanding installed base, which together are expected to support sequential revenue gains and gradual EPS improvement in the upcoming release.